PALISADE BIO INC (PALI) Stock News

USA - NASDAQ:PALI - US6963894026 - Common Stock

2.1099 USD

+0.26 (+14.05%)

Last: 10/29/2025, 3:55:04 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PALI Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Palisade Bio, Inc.

Palisade Bio Appoints Sharon Skare as Vice President, Global Head of Clinical Operations

9 days ago - By: Purcell & Lefkowitz LLP

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Palisade Bio, Inc. (NASDAQ: PALI)

9 days ago - By: Palisade Bio, Inc.

Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)

16 days ago - By: Palisade Bio, Inc.

Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108

20 days ago - By: Palisade Bio, Inc.

Palisade Bio Announces Cancellation of Special Meeting of Stockholders

a month ago - By: Stocktwits

News Image

Palisade Bio Stock Climbs To 9-Month High After $120M Stock Offering; Retail Sees More Gains Ahead

21 days ago - By: Benzinga

Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut

23 days ago - By: Benzinga - Mentions: IONR DFLI CRML AIP ...

Why AMD Shares Are Trading Higher By Over 34%; Here Are 20 Stocks Moving Premarket

a month ago - By: Palisade Bio, Inc.

Palisade Bio Announces Closing of Upsized $138 Million Public Offering of Common Stock and Including Full Exercise of Over-Allotment Option

a month ago - By: Palisade Bio, Inc.

Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock

a month ago - By: Palisade Bio, Inc.

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

a month ago - By: Palisade Bio, Inc.

Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

a month ago - By: Palisade Bio, Inc.

Palisade Bio Reports Positive PALI-2108 Phase 1b Clinical Data

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Reports 100% Clinical Response in Phase 1b Ulcerative Colitis Cohort with Novel PDE4 Inhibitor, PALI-2108

3 months ago - By: Palisade Bio, Inc.

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China